MEMORANDUM DECISION
HORNBY, District Judge.
This case involves the interpretation of 28 U.S.C. § 1782(a). That statute provides that a United States district court may, upon the application of any interested person, order a person residing in the district to give testimony or a statement or to produce documents for use in a foreign proceeding. The question here is to what degree this discretionary authority should depend on the applicant’s ability to compel such testimony or document production in the foreign jurisdiction and whether a United States District Judge must consider foreign law in making a decision. I find that the statute reflects a congressional judgment in favor of liberal disclosure and does not require an American judge to parse foreign law. I GRANT this application to obtain testimony and documents.
Factual and Procedural Background
Asta Medica, S.A.; Laboratories Sarget, S.A.; Dagra, BV; and Napp Laboratories, Ltd. (hereafter “Asta Medica”) are European pharmaceutical companies that are involved in a long-running patent dispute with Pfizer, Inc. Litigation is underway in France, Belgium, England and the Netherlands. The dispute concerns the patent for a method of processing the antibiotic doxy-cycline. During the course of the French litigation, Asta Medica became aware of previously unknown information it believes affects the validity of Pfizer’s patent claim. Specifically, Asta Medica alleges that Pfizer may have derived the process from an Italian Company, Ankerfarm, S.p.A., in the early 1970’s while Pfizer and Ankerfarm were engaged in negotiations over a proposed joint venture. Pfizer representatives allegedly visited the Ankerfarm facility in Milan and met with Ankerfarm employees working on the doxycycline processing technology. Pfizer ultimately chose not to pursue the joint venture, but subsequently obtained its own patents on the process. Asta Medica believes that Pfizer’s patents are invalid because the technology in question was already in the public domain by virtue of the earlier nonconfidential disclosures of Ankerfarm.
Asta Medica wishes to obtain documents and testimony from Pfizer employees who were involved in Pfizer’s dealings with Ankerfarm. Asta Medica argues that these employees may have information that directly undercuts Pfizer’s patent infringement claims, testimony that might be critical in the ongoing European litigation. Asta Medica filed an
ex parte
application in this District for United States judicial assistance under 28 U.S.C. § 1782, seeking testimony of David W. Moriarty, a former Pfizer employee now living in York, Maine. Asta Medica also sought a subpoena
duces tecum.
Magistrate Judge Cohen initially granted the
ex parte
application, but Pfizer and Moriarty (hereinafter “Pfizer”), once notified, moved to quash the. subpoena. Pfizer maintained that a private party invoking a court’s assistance under § 1782 had to show that the requested information
was discoverable under the law of foreign jurisdiction. Judge Cohen then granted Pfizer’s motion to quash the subpoena, stating that Asta Medica “failed to show that the requested discovery is permitted by any of the foreign tribunals involved here as a matter of right and without special leave of and/or supervision by the tribunal.” Asta Medica has objected.
For reasons that appear in this opinion, I conclude that an applicant under § 1782(a) need not surmount the hurdles that the Magistrate Judge’s decision imposes and that the Magistrate Judge’s decision is accordingly incorrect on the law. Since the parties have had an abundant opportunity to submit all their legal arguments as well as affidavits concerning foreign law, I will resolve the matter rather than resubmit it to the Magistrate Judge.
Since this is a case of first impression in this Circuit, a thorough review of the language and history of the statute is in order.
Section 1782
Two important contextual observations. First, this is not a “discovery” ease in the American sense of the term. This is not a search simply for information “reasonably calculated to lead to the discovery of admissible evidence.” Fed.R.Civ.P. 26(b)(1). Instead, what the applicant seeks here are testimony and documents that can be used in a foreign tribunal under a statute specifically tailored to that end. 28 U.S.C. § 1782(a);
cf. In re Letter of Request from the Crown Prosecution Serv. of the U.K.,
870 F.2d 686, 693 (D.C.Cir.1989).
Second, and in any event, the statutory language in question was enacted in 1964, before today’s severe disquiet over discovery abuse. In the early 1960’s most observers viewed the search for information we sometimes call “discovery” as a positive attribute of American judicial processes rather than as a source of the abuse, delay and cost decried by today’s critics. The content of § 1782 cannot be fully appreciated outside this historical context.
In amending § 1782 in 1964,
Congress substantially broadened the power of federal courts to assist foreign litigants. The Senate Report stated explicitly that “the proposed revision of section 1782 ... clarifies and
liberalizes
existing U.S. procedures for assisting foreign and international tribunals
and litigants
in obtaining oral and documentary evidence in the United States.... ” Senate Report,
supra,
at 3788 (emphasis supplied). A spirit of openhandedness permeates the amendment. For ex
ample, Congress expanded the class of litigation in which § 1782 could be used, specifying that district courts could now assist international courts as well as foreign courts. Congress also broadened the category of institutions that could seek assistance by using the term “tribunal” so that various administrative proceedings would be covered as well.
Another liberalization was deletion of the requirement that foreign litigation actually be pending. Under the revision of the statute, “[i]t is not necessary ... for the proceeding to be pending at the time the evidence is sought, but only that the evidence is eventually to be used in such a proceeding.”
See
Smit,
International Litigation, supra,
at 1026.
Of particular relevance in this case is the addition of language allowing private litigants to use the statute. Before 1964, letters roga-tory were the only method available for obtaining testimony or documents under § 1782, a procedure requiring the foreign tribunal or official to initiate the process.
Free access — add to your briefcase to read the full text and ask questions with AI
MEMORANDUM DECISION
HORNBY, District Judge.
This case involves the interpretation of 28 U.S.C. § 1782(a). That statute provides that a United States district court may, upon the application of any interested person, order a person residing in the district to give testimony or a statement or to produce documents for use in a foreign proceeding. The question here is to what degree this discretionary authority should depend on the applicant’s ability to compel such testimony or document production in the foreign jurisdiction and whether a United States District Judge must consider foreign law in making a decision. I find that the statute reflects a congressional judgment in favor of liberal disclosure and does not require an American judge to parse foreign law. I GRANT this application to obtain testimony and documents.
Factual and Procedural Background
Asta Medica, S.A.; Laboratories Sarget, S.A.; Dagra, BV; and Napp Laboratories, Ltd. (hereafter “Asta Medica”) are European pharmaceutical companies that are involved in a long-running patent dispute with Pfizer, Inc. Litigation is underway in France, Belgium, England and the Netherlands. The dispute concerns the patent for a method of processing the antibiotic doxy-cycline. During the course of the French litigation, Asta Medica became aware of previously unknown information it believes affects the validity of Pfizer’s patent claim. Specifically, Asta Medica alleges that Pfizer may have derived the process from an Italian Company, Ankerfarm, S.p.A., in the early 1970’s while Pfizer and Ankerfarm were engaged in negotiations over a proposed joint venture. Pfizer representatives allegedly visited the Ankerfarm facility in Milan and met with Ankerfarm employees working on the doxycycline processing technology. Pfizer ultimately chose not to pursue the joint venture, but subsequently obtained its own patents on the process. Asta Medica believes that Pfizer’s patents are invalid because the technology in question was already in the public domain by virtue of the earlier nonconfidential disclosures of Ankerfarm.
Asta Medica wishes to obtain documents and testimony from Pfizer employees who were involved in Pfizer’s dealings with Ankerfarm. Asta Medica argues that these employees may have information that directly undercuts Pfizer’s patent infringement claims, testimony that might be critical in the ongoing European litigation. Asta Medica filed an
ex parte
application in this District for United States judicial assistance under 28 U.S.C. § 1782, seeking testimony of David W. Moriarty, a former Pfizer employee now living in York, Maine. Asta Medica also sought a subpoena
duces tecum.
Magistrate Judge Cohen initially granted the
ex parte
application, but Pfizer and Moriarty (hereinafter “Pfizer”), once notified, moved to quash the. subpoena. Pfizer maintained that a private party invoking a court’s assistance under § 1782 had to show that the requested information
was discoverable under the law of foreign jurisdiction. Judge Cohen then granted Pfizer’s motion to quash the subpoena, stating that Asta Medica “failed to show that the requested discovery is permitted by any of the foreign tribunals involved here as a matter of right and without special leave of and/or supervision by the tribunal.” Asta Medica has objected.
For reasons that appear in this opinion, I conclude that an applicant under § 1782(a) need not surmount the hurdles that the Magistrate Judge’s decision imposes and that the Magistrate Judge’s decision is accordingly incorrect on the law. Since the parties have had an abundant opportunity to submit all their legal arguments as well as affidavits concerning foreign law, I will resolve the matter rather than resubmit it to the Magistrate Judge.
Since this is a case of first impression in this Circuit, a thorough review of the language and history of the statute is in order.
Section 1782
Two important contextual observations. First, this is not a “discovery” ease in the American sense of the term. This is not a search simply for information “reasonably calculated to lead to the discovery of admissible evidence.” Fed.R.Civ.P. 26(b)(1). Instead, what the applicant seeks here are testimony and documents that can be used in a foreign tribunal under a statute specifically tailored to that end. 28 U.S.C. § 1782(a);
cf. In re Letter of Request from the Crown Prosecution Serv. of the U.K.,
870 F.2d 686, 693 (D.C.Cir.1989).
Second, and in any event, the statutory language in question was enacted in 1964, before today’s severe disquiet over discovery abuse. In the early 1960’s most observers viewed the search for information we sometimes call “discovery” as a positive attribute of American judicial processes rather than as a source of the abuse, delay and cost decried by today’s critics. The content of § 1782 cannot be fully appreciated outside this historical context.
In amending § 1782 in 1964,
Congress substantially broadened the power of federal courts to assist foreign litigants. The Senate Report stated explicitly that “the proposed revision of section 1782 ... clarifies and
liberalizes
existing U.S. procedures for assisting foreign and international tribunals
and litigants
in obtaining oral and documentary evidence in the United States.... ” Senate Report,
supra,
at 3788 (emphasis supplied). A spirit of openhandedness permeates the amendment. For ex
ample, Congress expanded the class of litigation in which § 1782 could be used, specifying that district courts could now assist international courts as well as foreign courts. Congress also broadened the category of institutions that could seek assistance by using the term “tribunal” so that various administrative proceedings would be covered as well.
Another liberalization was deletion of the requirement that foreign litigation actually be pending. Under the revision of the statute, “[i]t is not necessary ... for the proceeding to be pending at the time the evidence is sought, but only that the evidence is eventually to be used in such a proceeding.”
See
Smit,
International Litigation, supra,
at 1026.
Of particular relevance in this case is the addition of language allowing private litigants to use the statute. Before 1964, letters roga-tory were the only method available for obtaining testimony or documents under § 1782, a procedure requiring the foreign tribunal or official to initiate the process. The 1964 amendment added a new method: proceedings could thereafter begin “upon the application of any interested person.” Thus, actual litigants can now seek a federal court’s assistance on their own.
But Congress has provided no standard to guide the courts’ determination of when to grant such assistance. Instead, it has left this decision wholly discretionary. In light of what we now know in 1992 about litigation costs and American discovery abuses, the 1964 amendment to § 1782 may appear naive. It is, nonetheless, the statute that Congress drafted.
The broadened power of the district courts under amended § 1782 was expressly designed to make the federal judicial system more generous in its assistance to foreign litigation. Both the legislative history and academic commentary bear out this reading of the statute.
The central inspiration for much of the work was a belief that if the United States were liberal with assistance in foreign litigation, foreign courts might later follow suit.
Thus, as the Senate Report put it, the goal of § 1782 was to “facilitate the conduct of [foreign] litigation.” Senate Report,
supra,
at 3783. Federal courts should, therefore, look askance at any interpretation that limits judicial discretion and makes it more difficult to obtain assistance requested in good faith under § 1782.
A rule requiring that the requested material first be shown to be discoverable in the foreign jurisdiction — the rule that Pfizer
persuaded the Magistrate Judge to adopt here — would be a severely onerous burden on both applicants and judges. In this case, for example, the lawyers have seen fit to present me with legal opinions from a variety of lawyers concerning the law of four separate foreign jurisdictions — the United Kingdom, France, the Netherlands and Belgium — and ask me to determine their respective laws on the taking of testimony and documents in reaching my decision on what is only a collateral issue to the proceedings underway or contemplated in the courts of those various countries. There is absolutely no evidence in the statute, the legislative history or the academic commentary explaining the statute’s enactment that suggests any congressional desire to impose on American courts the burden of investigating foreign law on matters such as admissibility of the evidence,
its discoverability in the American or any other sense,
or the authority of foreign tribunals to order such testimony or documents in aid of their own judicial proceedings. In the absence of any suggestion that Congress intended to impose such a burden, and given that Congress was seeking to
liberalize
the processes available to foreign litigants seeking evidence here, I conclude that resolution of these foreign law issues is not necessary to the exercise of § 1782 discretion.
A fortiori
I conclude,
contrary to the Magistrate Judge, that an applicant need not show that he could actually obtain the information in the foreign country as a matter of right without special permission from the foreign tribunal.
Instead, in granting authority to district judges to order testimony or documents for use in foreign litigation, Congress specifically made its exercise wholly discretionary. Under the statute, a district court “may” order testimony or documents; the statute does not direct the court to do so. I conclude that it is enough to determine that the subject matter is generally pertinent, and that improper goals or effects, such as harassment and unnecessary expense and delay, are minimized. Pfizer has argued that the information being sought by the applicants here is irrelevant to the foreign litigation and that the request therefore constitutes an abuse of § 1782.
I conclude, however, that the applicant Asta Medica has sought testimony and documents that on their face appear to have a bearing on the patents the parties are disputing in the foreign jurisdictions. Here, Pfizer and Moriarty have not demonstrated that the testimony and documents are sought solely for harassment purposes or delay. On the other hand, I cannot determine the utility of the testimony and documents at this stage of the foreign proceedings (the foreign lawyers’ affidavits express conflicting views on the subject). I
conclude that in order to minimize any possibility of harassment, unnecessary expense or delay, it is appropriate and within the exercise of a sound discretion to order Asta Medica to pay the reasonable attorney fees in connection with the taking of the testimony and documents.
Accordingly, the decision of the Magistrate Judge is hereby VACATED and the application of Asta Medica, S.A. for an order to take the testimony of David W. Moriarty, Jr. and subpoena duces tecum is GRANTED upon the condition that Asta Medica pay to Pfizer the reasonable attorney fees for one attorney to travel to, attend and participate in the deposition and taking of documents.
Multidistrict Cases
(Docket Nos. 92-6-P-H, 92-7-P-H, 92-8-P-H, 92-9-P-H)
The applicants have attempted to use § 1782 to subpoena several other Pfizer employees living in other states. They are: Thomas Mott Brennan in California; Her-mann Faubl in Illinois; Barry Malcom Bloom and Irving Maurice Goldman in Connecticut; and Irving Maurice Goldman in New York (the applicants attempted to subpoena Goldman in New York, but later learned that he lived and worked in Connecticut). All these individuals are present or former Pfizer employees who were somehow involved in Pfizer’s negotiations with Ankerfarm in the early 1970’s. Pfizer has opposed all the applications.
On September 16, 1991, Pfizer filed a motion before the Judicial Panel on Multi-district Litigation (“JPMDL”) requesting that the panel consolidate all the cases and transfer them either to the District of Maine or to the Northern District of Illinois. On December 16, 1991, the Panel transferred all the cases to the District of Maine, noting that the action here was the most advanced of the five.
I have not yet consolidated these cases, and my decision in Civil No. 91-328-P-H thus focuses only on the application to take discovery from David W. Moriarty. However, there are no apparent major distinctions between this case and the cases transferred here by the JPMDL. The parties therefore have 14 days from the date of this decision to SHOW CAUSE why those cases should not be controlled by the decision in Civil No. 91-328-P-H.
Joinder
Finally, a Portuguese company called Hovione Sociedade Quimica, S.A. (hereinafter “Hovione”) has filed a motion to join the subpoena litigation begun by Asta Medica. Pfizer objects on the ground that this motion should properly be captioned a motion to intervene under Rule 24 of the Federal Rules of Civil Procedure, rather than as a motion to join under Rule 20.
I first note that an application for assistance under § 1782 is a somewhat atypical procedure. It does not fit comfortably within the contours of the Federal Rules of Civil Procedure, which contemplate adversarial trial-type proceedings. Nonetheless, I think it is most appropriate to treat Ho-vione’s motion as a motion to intervene. Such treatment is consistent with Rule l’s admonition to construe the Federal Rules so as to “secure the just, speedy, and inexpensive determination” of matters before the Court. I find that the papers filed by Hovione thus far adequately demonstrate that Hovione’s request has questions of law and fact in common with the application of Asta Medica. Fed.R.Civ.P. 24(b). I further conclude that the motion is timely under the test most recently articulated by the First Circuit in
Banco Popular de Puerto Rico v. Greenblatt,
964 F.2d 1227, 1231 (1st Cir.1992).
The First Circuit held in
Banco Popular
that four factors must be con
sidered when passing on the timeliness of a motion to intervene: the putative inter-venor’s knowledge of the pending action, the prejudice to the movant, prejudice to the non-movant, and any exceptional circumstances militating for or against intervention.
Hovione’s motion came seven months after the initial application by Asta Medica and five months after the case was appealed to this court. The motion was filed before oral argument was held and counsel for Hovione was present at the oral argument. Hovione attempted intervention when it could still make contributions to the protection of its rights and interests. I thus find that Hovione’s motion is reasonably prompt.
Id.
at 1231.
I see no substantial prejudice accruing to Pfizer if this motion is granted. The burden of having another party present at Moriarty’s deposition is minimal. If the motion were denied Hovione could file an application for assistance on its own. This is a small burden, but would involve unnecessary expense and delay. Moreover, as the First Circuit noted in
Banco Popular,
since Hovione “enjoys a significant probability of success on the merits” in the action presently before the court,
id.
at 1232, denying intervention would, therefore, be prejudicial to Hovione.
Finally, the unique procedural status of this case and the interest in judicial and clerical economy both militate in favor of granting the motion. The issue before the court is fairly narrow on both factual and legal grounds; since it seems clear that the information Hovione seeks is essentially identical to that sought by Asta Medica, allowing intervention imposes no burden. Denying the motion would cause the commencement of a new round of filings, simply delaying the resolution of Hovione’s request.
Accordingly, Hovione’s motion is GRANTED.
SO ORDERED.